Celldex to Present 12-Week Barzolvolimab Phase 2 Study Results in Chronic Inducible Urticaria at ACAAI 2024

HAMPTON, N.J., Oct. 25, 2024 – Celldex Therapeutics, Inc. (NASDAQ:CLDX) has revealed the 12-week findings from its Phase 2 clinical trial of barzolvolimab, targeting two prevalent types of chronic inducible urticaria (CIndU) – cold urticaria (ColdU) and symptomatic dermographism (SD). These findings will be showcased in a late-breaking oral presentation at the American College of Allergy, Asthma & Immunology’s (ACAAI) Annual Scientific Meeting in Boston, which runs from October 24-28, 2024.

The presentation details are as follows:
Title: Positive Efficacy and Favorable Safety of Barzolvolimab in Chronic Inducible Urticaria: Phase 2 Trial Results
Presenter: Jonathan Bernstein, MD, Professor of Clinical Medicine, Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of Cincinnati Medical Center, and Partner, Bernstein Allergy Group and Clinical Research Center
Session: LBA003: Distinguished Industry & Late-breaking Oral Abstracts
Date/Time: Saturday, October 26 at 5:43 pm ET

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering the intersection of mast cell biology with the development of innovative therapies for patients facing severe inflammatory, allergic, autoimmune, and other debilitating conditions. Their pipeline includes antibody-based treatments designed to interact with the human immune system and/or directly influence pivotal pathways to enhance patient outcomes.